What's Included

Section 1 - Antipsychotics (Chapter 29)

1. Chlorpromazine - Low-potency typical; α1 > D2; high sedation/autonomic side effects, moderate EPS
2. Haloperidol - High-potency typical; D2 dominant; highest EPS, minimal sedation/autonomic effects
3. Aripiprazole - Unique D2/5-HT1A partial agonist; no EPS, no metabolic syndrome, activating
4. Clozapine - Prototype atypical; treatment-resistant schizophrenia; agranulocytosis + seizure risk; no EPS
5. Olanzapine - Broad receptor blockade; worst metabolic syndrome (after clozapine); minimal EPS
6. Risperidone - D2 + 5-HT2A antagonist; dose-dependent EPS; highest prolactin elevation among atypicals

Section 2 - Parkinson's Drugs (Chapter 28)

1. Levodopa - Dopamine precursor; gold-standard; wears off, dyskinesias, motor fluctuations
2. Pramipexole - D2/D3 agonist; impulse control disorders; sleep attacks; good for RLS
3. Rasagiline - Irreversible MAO-B inhibitor; serotonin syndrome risk; no tyramine restriction at therapeutic doses
4. Entacapone - Peripheral COMT inhibitor; extends levodopa effect; orange urine; no hepatotoxicity (unlike tolcapone)

Section 3 - Antiseizure Drugs (Chapter 24)

1. Phenytoin - Na+ channel; zero-order kinetics (narrow therapeutic window); gingival hyperplasia; hirsutism
2. Carbamazepine - Na+ channel; autoinduction; hyponatremia; aplastic anemia; Stevens-Johnson in HLA-B*1502
3. Valproate - Broadest spectrum; most teratogenic; hepatotoxicity; inhibits lamotrigine metabolism; tremor/weight gain
4. Lamotrigine - Na+ + Ca2+ channel; SJS risk (slow titration!); good for bipolar depression; safe in breastfeeding
5. Gabapentin - α2δ Ca2+ subunit (NOT GABA receptors); no drug interactions; renal excretion; neuropathic pain

Section 4 - Anxiolytics/Hypnotics (Chapter 22)

1. Alprazolam - Short-acting BZD; GABA-A α-freq increase; panic disorder; high withdrawal severity
2. Diazepam - Long-acting BZD; status epilepticus, alcohol withdrawal; active metabolites; self-tapering
3. Flumazenil - BZD competitive antagonist; short t½ (1 hour - re-sedation risk); precipitates withdrawal
4. Zolpidem - Non-BZD GABA-A α1-selective; sleep; no active metabolites; sleepwalking/sleep-driving (black box)
5. Buspirone - 5-HT1A partial agonist; GAD; no dependence/sedation; 2-4 week onset; fails in ex-BZD users

Opioids Section (Chapter 31)

• Full agonists: Morphine (prototype), Fentanyl (100x potency), Codeine (prodrug-CYP2D6), Oxycodone, Methadone (QTc, NMDA), Meperidine (normeperidine seizures/serotonin syndrome risk)
• Partial agonist: Buprenorphine (Suboxone for OUD, ceiling effect on respiratory depression)
• Mixed agonist-antagonists: Nalbuphine (κ-agonist/μ-antagonist)
• Pure antagonists: Naloxone (IV, short t½ - re-narcotization risk), Naltrexone (oral/monthly injection, OUD + alcohol use disorder), Methylnaltrexone (peripheral, OIC only)